好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Baseline Physical Activity Profiles in CREST-2 Trial Participants
Cerebrovascular Disease and Interventional Neurology
P1 - Poster Session 1 (5:30 PM-6:30 PM)
3-056

Based on data from a trial of intracranial stenosis patients, we aimed to evaluate the hypothesis that <40% of carotid stenosis subjects will have optimal physical activity levels. We also assessed key subgroups to determine patterns of physical activity.

The importance of physical activity in preventing major vascular events has received increased attention in the past decade. Due to the inclusion of the INTERVENT lifestyle modification program, the CREST2 trial provides a unique opportunity to study physical activity profiles in patients with severe asymptomatic extracranial carotid stenosis.

We analyzed 1087 CREST2 participants with baseline data on physical activity. The Physician-based Assessment and Counseling for Exercise (PACE) score is recorded for each patient and dichotomized as “in target” (4-8 points) or “out of target” (<4 points). A PACE score of <4 indicates a subject who does not engage in regular exercise. Results are analyzed for the entire trial. Chi square testing and t-tests were performed for evaluation of subgroup differences.

The mean age of the study population is 69.5±7.8 years (60% male). The median PACE score at baseline is 4.0 (mean 3.8±2.1; IQR 2 to 6). The Table shows baseline characteristics of patients by mean PACE score. Being male, not having diabetes mellitus, having a body mass index <30kg/m2, being a non-smoker, and not having a history of peripheral arterial disease were associated with significantly higher mean PACE scores (P<0.01).

 

Table. Mean PACE scores by baseline characteristics for participants in CREST2.

Baseline Characteristic

Mean + SD PACE score

p-value

<65

3.7+2.0

0.21

65+

3.9+2.1

Male

4.0+2.2

<0.0001

Female

3.5+2.0

White

3.8+2.1

0.25

Non white

4.0+2.1

Normotensive

3.8+2.1

0.14

Hypertensive

4.1+2.2

Diabetic

3.6+2.0

0.008

Non-Diabetic

3.96+2.2

Dyslipidemic

3.8+2.1

0.97

Not Dyslipidemic

3.8+1.9

BMI > 30 kg/m2

3.3+1.9

<0.0001

BMI <30 kg/m2

4.1+2.2

 

 

 

 

Current smoker

3.2+2.0

<0.0001

Non smoker

4.0+2.1

CAD

3.8+2.1

0.28

No CAD

3.9+2.1

PAD

3.5+2.0

0.007

No PAD

3.9+2.1

CABG

3.9+2.1

0.86

No CABG

3.8+2.1

Prior Stent

3.7+2.0

0.09

No Stent

3.9+2.2

Contralateral CAS or CEA

3.7+2.2

0.23

None

3.9+2.1

Prior Stroke or TIA

3.6+2.1

0.14

None

3.9+2.1


We have defined several patient groups with asymptomatic carotid stenosis that have suboptimal physical activity. These results provide opportunities for targeted efforts to improve primary stroke prevention. These baseline data will also allow investigators to determine if trial involvement and the INTERVENT program leads to improvement in the level of physical activity.

Authors/Disclosures
Seemant Chaturvedi, MD, FAHA, FAAN (University of Maryland)
PRESENTER
Dr. Chaturvedi has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Bayer. Dr. Chaturvedi has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Chaturvedi has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for American Heart Association. The institution of Dr. Chaturvedi has received research support from NINDS.
Tanya N. Turan, MD, FAAN (Medical University of South Carolina) Dr. Turan has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Pfizer/Merck. Dr. Turan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Gore Inc. Dr. Turan has received publishing royalties from a publication relating to health care. Dr. Turan has received publishing royalties from a publication relating to health care.
No disclosure on file
Jenifer Voeks Jenifer Voeks has nothing to disclose.
Marc I. Chimowitz, MD (MUSC Stroke Center) An immediate family member of Dr. Chimowitz has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Gore. Dr. Chimowitz has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for NoNo Inc. The institution of Dr. Chimowitz has received research support from NIH.
Virginia J. Howard, PhD (University of Alabama At Birmingham) The institution of Dr. Howard has received research support from NIH. The institution of an immediate family member of Dr. Howard has received research support from NIH.
George Howard, PhD (UAB School of Public Hlth) Dr. Howard has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Bayer.
Kevin M. Barrett, MD, FAAN (Mayo Clinic) Dr. Barrett has nothing to disclose.
Robert D. Brown, Jr., MD, MPH, FAAN (Mayo Clinic) Dr. Brown has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for Craig H Neilsen Foundation. The institution of Dr. Brown has received research support from National Institutes of Health/NINDS. Dr. Brown has received publishing royalties from a publication relating to health care.
Ronald M. Lazar, PhD, FAHA, FAAN, FAAN (University of Alabama At Birmingham) Dr. Lazar has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for DiaMedica Therapeutics Inc. . The institution of Dr. Lazar has received research support from National Institutes of Health. Dr. Lazar has received publishing royalties from a publication relating to health care.
No disclosure on file
Claudia Moy, PhD Claudia Moy, PhD has nothing to disclose.
No disclosure on file
Bart Demaerschalk, MD, MSc, FRCPC, FAAN (Mayo Clinic) Dr. Demaerschalk has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genentech. Dr. Demaerschalk has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Shionogi. Dr. Demaerschalk has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for The Neurologist . The institution of Dr. Demaerschalk has received research support from NICHD.
No disclosure on file
Lawrence R. Wechsler, MD, FAAN (UPMC) Dr. Wechsler has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for American Neurological Association. Dr. Wechsler has stock in Forest Devices.
Brajesh K. Lal (University of Maryland) Brajesh K. Lal has nothing to disclose.
James F. Meschia, MD, FAAN (Mayo Clinic) The institution of Dr. Meschia has received research support from NINDS. The institution of Dr. Meschia has received research support from NINDS.
Thomas G. Brott, MD, FAAN (Mayo Clinic) Dr. Brott has nothing to disclose.